|
Golbahar et al. 2008 [17]
|
Bahrain
|
124/130
|
2
|
Plasma
|
F: Hcy > 15 μmol/l; M: Hcy > 12 μmol/l
|
8
|
1, 2, 3, 4, 7, 12, 13
|
|
Vaccaro et al , 1997 [8]
|
Japan
|
11/14
|
1
|
Plasma
|
≥10 μmol/
|
6
|
1, 2, 6, 8, 9, 13
|
|
Hofmann et al., 1998 [18]
|
France
|
26/49
|
1
|
Plasma
|
Preload > 15.8 μmol/l or Postload > 31.1 μmol/l
|
8
|
1, 2, 3, 4, 6, 7, 9
|
|
Hoogeveen et al., 2000 [5]
|
Netherlands
|
534/91
|
2
|
serum
|
>16 μmol/l
|
7
|
1, 2, 7, 8, 9
|
|
Buysschaert et al., 2000 [19]
|
Belgium
|
38/84
|
1
|
Plasma
|
>15 μmol/l
|
7
|
1, 2, 3, 5, 6, 10, 11, 12
|
|
Agullo-Ortuno et al., 2002 [3]
|
Spain
|
18/71
|
1, 2
|
Plasma
|
F >13.9 μmol/l, M >15.6 μmol/l
|
5
|
9, 10, 11, 12
|
|
Goldstein et al., 2004 [4]
|
Israel
|
84/251
|
NA
|
Plasma
|
>15 μmol/l
|
7
|
1, 6, 14
|
|
de Luis et al., 2005 [20]
|
Spain
|
22/133
|
2
|
Plasma
|
> 15 μmol/l
|
6
|
1, 6, 7, 8, 9
|
|
Satyanarayana et al., 2011 [21]
|
US
|
141/159
|
2
|
Plasma
|
> 12 μmol/l
|
7
|
1, 5, 9, 11
|
